Kirkland Advises Crown Laboratories on $924 Million Acquisition of Revance

Advising firms

The announcement does not name individual lawyers.

Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.

Stated terms

Stated value

USD 924m ($924 million)

What the figure measures

Total transaction value

Client

Crown Laboratories, Inc.Buy-side

Counterparties

Revance Therapeutics, Inc. (Sell-side)